


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1 (Currently amended). Sulfonamide derivatives according to formula I



with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ and Ar² are independently from each other substituted or unsubstituted aryl or heteroaryl groups,

X is O or S, preferably O;

R¹ is hydrogen or a C₁-C₆-alkyl group, or R¹ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar¹;

n is an integer from 0 to 5, preferably between 1-3 and most preferred 1;

Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said

Appln. No. 10/070,954

Amd. dated October 20, 2004

Reply to Office Action of September 20, 2004

ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide,

with the proviso that if Ar¹ is 4-chlorophenyl, X is O, R¹ is H, Ar² is thienyl, and Y is not a piperidino group which is para-substituted by 2-hydroxyethyl while Y is a piperazino group, L¹ shall not be diphenylmethyl, benzo[1,3]dioxol-5-yl methyl, 4-methoxy phenyl, 2-hydroxyethyl, methyl, 4-chlorophenyl methyl, and if Y is a 3-methyl piperazino, L¹ shall not be 4-chlorophenyl methyl, and if Y is piperazino-3,5-dione, L¹ shall not be 2-phenyl ethyl,

with the further proviso that if Ar¹ is phenyl 4-chlorophenyl, X is O, R¹ is H, Ar² is thienyl, and Y is not a piperidino group which is substituted in its β position by a benzo (5,6) cyclohepta (1,2b) pyridine or a benzo (5,6) cyclohept (3,4)ene (1,2b) pyridine while Y is a piperidino group with L¹ being H, L² shall not be 2-hydroxy ethyl;


with the further proviso that if Y is a piperidino- or a pyrrolidino group being substituted at the β -position of the piperidino- or a pyrrolidino nitrogen by a benzo[5,6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept (3,4) ene [1, 2b]pyridine, while Ar² is thienyl, X is oxygen, R¹ is hydrogen and n is 1, Ar¹ shall not be a phenyl group;

with the further proviso that if X is oxygen, R¹ is hydrogen and n is 1, while Y is a piperazine, said piperazine at the para-nitrogen shall not be substituted by a group containing a benzamidine or a protected form thereof;

with the further proviso that the compounds 2-{[2-(benzoylaminomethyl)-thiophene]-5-sulfonyl}-1,2,3,5,6,7-hexahydro-N,N-dipropylcyclopent[f]isoindol-6-amine and N-[[5-[[7-cyano-1,2,3,5-tetrahydro-1-(1H-imidazol-4-yl-methyl)-3-(phenylmethyl)-4H-1,4-benzodiazepin-4-yl]sulfonyl]-2-thienyl]methyl] benzamide and its hydrochloride are excluded;

with the final proviso that if X is oxygen and Y is a 4-8 membered saturated cyclic alkyl containing one or two nitrogen atoms, Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

2 (Previously presented). Sulfonamide derivatives according to formula I



with its geometrical isomers, in an optically active form as enantiomers, dia-stereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ and Ar² are independently from each other substituted or unsubstituted aryl or heteroaryl groups,

X is O or S, preferably O;

R¹ is hydrogen or a C₁-C₆-alkyl group, or R¹ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar¹;

n is an integer from 0 to 5, preferably between 1-3 and most preferred 1;

Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide, for use as a medicament;

with the proviso that if Y is a piperidino- or a pyrrolidino group being substituted at the β -position of the piperidino- or a pyrrolidino nitrogen by a benzo[5, 6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept (3,4) ene [1, 2b]pyridine, while Ar² is thienyl, X is oxygen, R¹ is hydrogen and n is 1, Ar¹ shall not be a phenyl group;


with the further proviso that if X is oxygen, R¹ is hydrogen and n is 1, while Y is a piperazine, said piperazine at the para-nitrogen shall not be substituted by a group containing a benzamidine or a protected form thereof;

with the further proviso that the compounds 2-{[2-(benzoylaminomethyl)-thio-phenyl]-5-sulfonyl}-1,2,3,5,6,7-

hexahydro-N,N-dipropylcyclopent[f]isoindol-6-amine and N-[[5-[[7-cyano-1,2,3,5-tetrahydro-1-(1H-imidazol-4-yl-methyl)-3-(phenylmethyl)-4H-1,4-benzodiazepin-4-yl]sulfonyl]-2-thienyl]methyl] benz-amide and its hydrochloride are excluded;

with the final proviso that if X is oxygen and Y is a 4-8 membered saturated cyclic alkyl containing one or two nitrogen atoms, Y shall not be substituted by a group (C=O)N(R,R') at the α -position of the sulfonamide nitrogen.

3 (Original). A sulfonamide derivative according to claim 1 or 2, wherein Y is a piperazino- or piperidino group of the general formula



whereby, L^1 and L^2 are independently selected from each other from the group comprising or consisting of H, substituted or unsubstituted C_1 - C_6 -aliphatic alkyl, substituted or unsubstituted C_2 - C_6 -alkenyl, substituted or unsubstituted C_2 - C_6 -alkynyl, substituted or unsubstituted cyclic C_4 - C_8 -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or L^1 and L^2 are independently selected from the group comprising or consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl,

aryl-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, -C(O)-OR³, -C(O)-R³, -C(O)-NR^{3'}R³, -NR^{3'}R³, -NR^{3'}C(O)R³, -NR^{3'}C(O)NR^{3'}R³, -(SO)R³, -(SO₂)R³, -NSO₂R³, -SO₂NR^{3'}R³,

with R³, R^{3'} being substituents independently selected from the group comprising or consisting of H, substituted or unsubstituted C₁-C₆-alkyl, substituted or unsubstituted C₂-C₆-alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-C₁-C₆-alkyl, substituted or unsubstituted heteroaryl-C₁-C₆-alkyl;


said aryl or heteroaryl groups being optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, C₁-C₆-thioalkoxy,

or L¹ and L² taken together form a 4-8-membered, substituted or unsubstituted saturated cyclic alkyl or heteroalkyl group; and

R⁶ is selected from the group comprising or consisting of hydrogen, substituted or unsubstituted C₁-C₆-alkyl, substituted or unsubstituted C₁-C₆-alkoxy, OH, halogen, nitro, cyano, sulfonyl, oxo (=O), and

n' is an integer from 0 to 4, preferably 1 or 2.

4 (Withdrawn). A sulfonamide derivative according to claim 1 or 2, wherein Y is a pyrrolidine, an azepan or a 1,4-diazepan moiety of the below formulas



wherein L^1 is selected from the group comprising or consisting of H, substituted or unsubstituted C_1 - C_6 -alkyl, substituted or unsubstituted C_2 - C_6 -alkenyl, substituted or unsubstituted C_2 - C_6 -alkynyl, substituted or unsubstituted cyclic C_4 - C_8 -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or L^1 and L^2 are independently selected from the group comprising or consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- C_1 - C_6 -alkyl, heteroaryl- C_1 - C_6 -alkyl, $-C(O)-OR^3$, $-C(O)-R^3$, $-C(O)-NR^{3'}R^3$, $-NR^{3'}R^3$, $-NR^{3'}C(O)R^3$, $-NR^{3'}C(O)NR^{3'}R^3$, $-(SO)R^3$, $-(SO_2)R^3$, $-NSO_2R^3$, $-SO_2NR^{3'}R^3$;

R^3 and $R^{3'}$ are substituents independently selected from the group comprising or consisting of H, substituted or unsubstituted C_1 - C_6 -alkyl, substituted or unsubstituted C_2 - C_6 -alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- C_1 - C_6 -alkyl, substituted or unsubstituted heteroaryl- C_1 - C_6 -alkyl;

R^6 is selected from the group comprising or consisting of hydrogen, substituted or unsubstituted C_1 - C_6 -alkyl, substituted or unsubstituted C_1 - C_6 -alkoxy, OH, halogen, nitro, cyano, sulfonyl, oxo (=O), sulfoxy, acyloxy, thioalkoxy and n' is an integer from 0 to 4, preferably 0.

5 (Previously presented). A sulfonamide derivative according to claim 1, wherein Ar^1 and Ar^2 are independently selected from the group comprising or consisting of phenyl, thienyl, furyl, pyridyl, optionally substituted by C_1 - C_6 -alkyl, preferably trihalomethyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, amino, acylamino, aminocarbonyl, C_1 - C_6 -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, C_1 - C_6 -thioalkoxy.


6 (Original). A sulfonamide derivative according to claim 5, wherein Ar^1 is an unsubstituted or substituted phenyl.

7 (Original). A sulfonamide derivative according to claim 5, wherein Ar^2 is an unsubstituted or substituted thienyl or furanyl group.

8 (Previously presented). A sulfonamide derivative according to claim 1, wherein Ar^1 is selected from a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer,

pyrazole and X is O, R¹ is hydrogen, n is 1, Ar² is thienyl or furanyl.

9 (Original). A sulfonamide derivative according to claim 8, wherein Y is



with (R⁶)_n, L¹ and L² being as above defined.

10 (Original). A sulfonamide derivative according to claim 9, wherein R⁶ is H, L² is H, L¹ is a 5-membered cyclic group containing 3 heteroatoms, preferably a triazole ring which is preferably fused with an unsubstituted or substituted aryl or heteroaryl; or L¹ is -C(O)-R³, or -NHR³;

with R³ being a substituent selected from the group comprising or consisting of C₁-C₁₂-alkyl, aryl, heteroaryl, aryl-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl;

said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, sulfonyl.

11 (Previously presented). A sulfonamide derivative according to claim 1, selected from the group consisting of:

4-chloro-N-[5-(piperazine-1-sulfonyl)-thiophen-2-yl-methyl]-benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-Chloro-N-{5-[4-(3-trifluoromethanesulfonyl-phenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl}-benzamide;

4-chloro-N-({5-[(4-pyridin-2-yl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

4-chloro-N-[(5-{[4-(4-fluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-({5-[(4-{2-nitrophenyl}piperazin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

4-chloro-N-({5-[(4-{4-nitrophenyl}piperazin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

4-chloro-N-[(5-{[4-(2-furoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-hydroxyphenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-morpholin-4-yl-2-oxoethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(pyridin-4-ylmethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-thien-2-ylethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3,5-dimethoxyphenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(cyclohexylmethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-methoxyphenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-benzylpiperazin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-phenylethyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-fluorobenzyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-cyanophenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-({5-[(4-{4-chloro-2-nitrophenyl}piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(6-methylpyridin-2-yl)piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[(4-hydroxy-4-phenylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-({5-[(4-benzoylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-({5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-({5-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[2-(methylanilino)-2-oxoethyl]piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[hydroxy(diphenyl)methyl]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(3-cyanopyrazin-2-yl)piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[(4-{5-nitropyridin-2-yl}piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-{[5-({4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{[5-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{[5-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

methyl 5-{4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazin-1-yl}-7-(trifluoromethyl)thieno[3,2-b]pyridine-3-carboxylate;

ethyl 2-{4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazin-1-yl}-5-cyano-6-methylnicotinate;

4-chloro-N-{[5-({4-[5-cyano-4,6-bis(dimethylamino)pyridin-2-yl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{[5-({4-[6-methyl-2-(trifluoromethyl)quinolin-4-yl]piperazin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

tert-butyl 4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazine-1-carboxylate;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

2-{4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazin-1-yl}-8-ethyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid;

7-{4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazin-1-yl}-1-ethyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid;

7-{4-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperazin-1-yl}-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;

4-chloro-N-[(5-{[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[(2E)-3-phenylprop-2-enyl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(3-phenylpropyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3,4,5-trimethoxyphenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(4-tert-butylbenzyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-hydroxyphenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N- { [5- ({ 4- [4- (trifluoromethyl)pyridin-2-
yl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N- [(5- { [4- (5-cyanopyridin-2-yl)piperazin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;

tert-butyl 1- [(5- { [(4-chlorobenzoyl) amino] methyl}thien-
2-yl)sulfonyl]piperidin-4-ylcarbamate;

4-chloro-N- ({ 5- [(4-phenylpiperazin-1-yl)sulfonyl]thien-
2-yl}methyl)benzamide;

4-chloro-N- { [5- (piperidin-1-ylsulfonyl)thien-2-
yl)methyl}benzamide;

4-chloro-N- [(5- { [4- (1-naphthyl)piperazin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- [(5- { [4- (3,4-dichlorophenyl)piperazin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- { [5- ({ 4- [3-
(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-2-
yl)methyl}benzamide;

4-chloro-N- { [5- ({ 3-hydroxy-4- [3-
(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)thien-2-
yl)methyl}benzamide;

4-chloro-N- [(5- { [4- (2-methylphenyl)piperazin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appl'n. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[(1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(benzyloxy)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

N-(4-chlorophenyl)-2-(5-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)sulfonyl}thien-2-yl)acetamide;

4-chloro-N-({5-[(4-hydroxypiperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-[(5-{[4-(4-acetylphenyl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(3,5-dichloropyridin-4-yl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-methoxyphenyl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-benzyl-4-hydroxypiperidin-1-yl)sulfonyl}thien-2-yl)methyl)-4-chlorobenzamide;

N-{[5-({4-[(2-tert-butyl-1H-indol-5-yl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{[5-({4-[(phenylacetyl)amino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(6-chloropyridin-2-yl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-chlorophenyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(2H-1,2,3-benzotriazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(4-chlorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-phenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[benzyl(methyl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{[5-({4-[3-(2,4-dichlorophenyl)-1H-pyrazol-5-yl]piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(5-thien-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2,3,4,5,6-pentamethylbenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(phenylacetyl)-1,4-diazepan-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N- { [5- ({ 4- [5- (4-methoxyphenyl) -1H-pyrazol-3-yl]piperidin-1-yl} sulfonyl) thien-2-yl] methyl} benzamide;

N- ({ 5- [(4-anilinopiperidin-1-yl) sulfonyl] thien-2-yl} methyl) -4-chlorobenzamide;

4-chloro-N- [(5- { [4- (3-phenyl-1,2,4-thiadiazol-5-yl) piperazin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

4-chloro-N- [(5- { [4- (2-phenylethyl) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

4-chloro-N- ({ 5- [(4-heptylpiperazin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

4-chloro-N- ({ 5- [(4-octylpiperazin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -4-chlorobenzamide;

2- (5- { [4- (1H-1,2,3-benzotriazol-1-yl) piperidin-1-yl] sulfonyl} thien-2-yl) -N- (4-chlorophenyl) acetamide;

2- { 1- [(5- { [(4-chlorobenzoyl) amino] methyl} thien-2-yl) sulfonyl] piperidin-4-yl} -2H-1,2,3-benzotriazole-5-carboxylic acid;

4-chloro-N- [(5- { [4- (5-chloro-1H-1,2,3-benzotriazol-1-yl) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

Appln. No. 10/070,954

Amd. dated October 20, 2004

Reply to Office Action of September 20, 2004

methyl 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylate;

methyl 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylate;

methyl 2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N-[(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[5-(trifluoromethyl)-1H-1,2,3-benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-(7-aza-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylic acid;

1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid;

Appln'. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-(2-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-({5-[(4-{6-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[(4-{5-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(2H-1,2,3-triazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

methyl 3-({1-[(5-{[(4-chlorobenzoyl)amino]-methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N- { [5- ({4- [3-
(methylsulfonyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

4-chloro-N- ({5- [(4- {3-nitroanilino} piperidin-1-
yl) sulfonyl] thien-2-yl} methyl) benzamide;

4-chloro-N- [(5- { [4- (2-methoxyanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] benzamide;

3- ({1- [(5- { [(4-chlorobenzoyl) amino] methyl} thien-2-
yl) sulfonyl] piperidin-4-yl} amino) benzamide;

4-chloro-N- { [5- ({4- [2-
(trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

4-chloro-N- ({5- [(4- {2-nitro-4-
[(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-
2-yl} methyl) benzamide;

4-chloro-N- [(5- { [4- (4-chloroanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] benzamide;

4-chloro-N- { [5- ({4- [4-
(trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

4-chloro-N- ({5- [(4- {4-
[(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-
2-yl} methyl) benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-({5-[(4-{2-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-({5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-({5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(2-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-({5-[4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(3-toluidino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-({5-[4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated October 20, 2004

Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-({3-nitropyridin-2-yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-4-chlorobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[4-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

4-chloro-N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[4-{3-[(butylamino)sulfonyl]anilino}piperidin-1-yl]sulfonyl}thien-2-yl)methyl)-4-chlorobenzamide;

Appln. No. 10/070,954

Amd. dated October 20, 2004

Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(3-ethylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(quinolin-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(quinolin-8-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-Chloro-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[(2E)-3-phenylprop-2-enoyl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[4-{4-nitrobenzoyl}piperazin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

N-({5-[(4-benzoylpiperazin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

4-chloro-N-{[5-({4-[4-(trifluoromethyl)benzoyl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-{[5-({4-[4-(dimethylamino)benzoyl]piperazin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(2-fluorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2,6-difluorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-fluorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-naphthoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(1-naphthoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2-nitrobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(2,1,3-benzoxadiazol-5-ylcarbonyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2,4,6-trifluorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(2,6-dichlorobenzoyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appl. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-({5-[(4-heptanoylpiperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{ [4-(quinolin-8-ylsulfonyl)piperazin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{ [4-(2,4-difluorobenzoyl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{ [4-(2,4-difluorobenzoyl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

3-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-{[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

3-nitro-N-{[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

3-nitro-N-{[5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-{[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

methyl 3-{[1-({5-[(3-nitrobenzoyl)amino]methyl}-thien-2-yl)sulfonyl]-piperidin-4-yl}amino}benzoate;

N-{[5-({4-[3-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

3-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

3-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-nitro-N- { [5- ({4- [2-
(trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

3-nitro-N- ({5- [(4- {2-nitroanilino} piperidin-1-
yl) sulfonyl] thien-2-yl} methyl) benzamide;

N- [(5- { [4- (4-chloroanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] -3-nitrobenzamide;

3-nitro-N- { [5- ({4- [4-
(trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

3-nitro-N- ({5- [(4- {4-
[(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-
2-yl} methyl) benzamide;

N- { [5- ({4- [4- (aminocarbonyl) anilino] piperidin-1-
yl] sulfonyl) thien-2-yl] methyl} -3-nitrobenzamide;

N- [(5- { [4- (3-propylanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] -3-nitrobenzamide;

N- [(5- { [4- (3-chloroanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] -4-nitrobenzamide;

4-nitro-N- [(5- { [4- (3-methoxyanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-nitro-N-{ [5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-{ [5-({4-[3-(dimethylamino)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-4-nitrobenzamide;

4-nitro-N-[(5-{[4-(3-propylanilino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-{ [5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

4-nitro-N-{ [5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-{ [5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-4-nitrobenzamide;

methyl 3-{[1-({5-[(4-nitrobenzoyl)amino]methyl}-thien-2-yl)sulfonyl]piperidin-4-yl}amino}benzoate;

3-{[1-({5-[(4-nitrobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino}benzamide;

4-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-nitro-N-([5-([4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-nitro-N-([5-([4-{2-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-([5-([4-(4-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-([5-([4-(4-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-nitro-N-([5-([4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-([5-([4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-([5-([4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-([5-([4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

N-([5-([4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-nitrobenzamide;

N-({5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-nitrobenzamide;

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-nitrobenzamide;

N-({5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-nitrobenzamide;

3-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

3-nitro-N-[(5-{[4-({3-nitropyridin-2-yl)amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-nitro-N-[(5-{[4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-{[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

3-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-{[5-({4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

3-nitro-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-4-nitrobenzamide;

4-nitro-N-[(5-{[4-({3-nitropyridin-2-yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-[(5-{[4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-{[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-nitrobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-{[5-({4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

N-({5-[4-{2-nitro-4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

3-nitro-N-[(5-{[4-(3-phenylpropyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-({5-[4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-({5-[4-{3-[(butylamino)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-(3-ethylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

2-Hydroxy-N-({5-[4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)benzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-2-hydroxybenzamide;

N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

3-methoxy-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-methoxy-N- { [5- ({4- [3-
(trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

N- { [5- ({4- [3- (dimethylamino) anilino] piperidin-1-
yl} sulfonyl) thien-2-yl] methyl} -3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (3-propylanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] benzamide;

3-methoxy-N- { [5- ({4- [3-
(methylsulfonyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

3-methoxy-N- { [5- ({4- [3-
(methylsulfanyl) anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

N- { [5- ({4- [3- (aminosulfonyl) anilino] piperidin-1-
yl} sulfonyl) thien-2-yl] methyl} -3-methoxybenzamide;

methyl 3- ({1- [(5- { [(3-methoxybenzoyl) amino] -
methyl} thien-2-yl) sulfonyl] piperidin-4-yl} amino) -benzoate;

N- { [5- ({4- [3- (aminocarbonyl) anilino] piperidin-1-
yl} sulfonyl) thien-2-yl] methyl} -3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (2-methoxyanilino) piperidin-1-
yl] sulfonyl} thien-2-yl) methyl] benzamide;

N- ({5- [(4- {3-nitroanilino} piperidin-1-
yl) sulfonyl] thien-2-yl} methyl) -3-methoxybenzamide;

Appl. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-methoxy-N-({[5-({4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-({5-[4-{2-nitroanilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide;

N-({[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide;

N-({[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-3-methoxybenzamide;

N-([5-{[4-(3-chloroanilino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-([5-{[4-(4-chloroanilino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-({[5-[4-4-((trifluoromethyl)sulfonyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl)benzamide;

N-({[5-[4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-({[5-[4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-methoxy-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-
2-yl)methyl}benzamide;

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
yl)methyl}-3-methoxybenzamide;

3-methoxy-N-({5-[(4-{3-
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-
2-yl)methyl}benzamide;

N-[(5-{[4-(4-hydroxyanilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-nitro-N-({5-[(4-{3-
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-
2-yl)methyl}benzamide;

4-nitro-N-({5-[(4-{3-
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-
2-yl)methyl}benzamide;

N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-({3-nitropyridin-2-yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-methoxybenzamide;

N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-{[4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-methoxy-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-({5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

3-methoxy-N-{[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appl'n. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

3-methoxy-N- { [5- ({4- [3- (morpholin-4-yl)sulfonyl)anilino]piperidin-1-yl} sulfonyl) thien-2-yl] methyl} benzamide;

3-methoxy-N- [(5- { [4- (2-phenylethyl) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

N- [(5- { [4- (3-benzylanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (3-phenylpropyl) piperazin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

3-methoxy-N- ({5- [(4- { [4- (trifluoromethyl) pyrimidin-2-yl] amino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

N- [(5- { [4- (3-cyclohexyl-4-hydroxyanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -3-methoxybenzamide;

N- ({5- [(4- {3- [(butylamino) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) -3-methoxybenzamide;

N- [(5- { [4- (3-ethylanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (5,6,7,8-tetrahydronaphthalen-1-ylamino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -5-nitro-1H-pyrazole-3-carboxamide;

Appl'n. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-2-oxo-1,2-dihydropyridine-3-carboxamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-2-thioxo-1,2-dihydropyridine-3-carboxamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3,4-dihydroxybenzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]pyridine-2-carboxamide;

N-[(5-{[4-(hexyloxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-({5-[(4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-methoxybenzamide;

4-chloro-N-[(5-{[4-(3-propylanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-{[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-{ [5- ({4- [3- (dimethylamino) anilino] piperidin-1-yl} sulfonyl) -2-furyl] methyl} benzamide;

4-chloro-N-{ [5- ({4- [3- (methylsulfonyl) anilino] piperidin-1-yl} sulfonyl) -2-furyl] methyl} benzamide;

4-chloro-N-{ [5- ({4- [3- (methylsulfonyl) anilino] piperidin-1-yl} sulfonyl) -2-furyl] methyl} benzamide;

N-{ [5- ({4- [3- (aminosulfonyl) anilino] piperidin-1-yl} sulfonyl) -2-furyl] methyl} -4-chlorobenzamide;

methyl 3- ({1- [(5- { [(4-chlorobenzoyl) amino] methyl} -2-furyl) sulfonyl] piperidin-4-yl} amino) benzoate;

3- ({1- [(5- { [(4-chlorobenzoyl) amino] methyl} -2-furyl) sulfonyl] piperidin-4-yl} amino) benzamide;

4-chloro-N- ({5- [(4- {3-nitroanilino} piperidin-1-yl) sulfonyl] -2-furyl} methyl) benzamide;

4-chloro-N- [(5- { [4- (2-methoxyanilino) piperidin-1-yl] sulfonyl} -2-furyl) methyl] benzamide;

4-chloro-N- { [5- ({4- [2- (trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) -2-furyl] methyl} benzamide;

4-chloro-N- ({5- [(4- {2-nitroanilino} piperidin-1-yl) sulfonyl] -2-furyl} methyl) benzamide;

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-{[5-({4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

4-chloro-N-({5-[4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl}benzamide;

N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}-4-chlorobenzamide;

4-chloro-N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

N-({5-[4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl}-4-chlorobenzamide;

4-chloro-N-({5-[4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl}benzamide;

N-({5-[4-anilinopiperidin-1-yl)sulfonyl]-2-furyl)methyl}-4-chlorobenzamide;

4-nitro-N-({5-[4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl}benzamide;

Appl'n. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

4-chloro-N-({5-[(3-{3-
[(trifluoromethyl)sulfonyl]anilino}pyrrolidin-1-
yl)sulfonyl]thien-2-yl)methyl}benzamide; and

4-chloro-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}azepan-1-yl)sulfonyl]thien-2-
yl)methyl}benzamide.

12 (Original). A sulfonamide derivative according to
claim 11, which is selected from the group consisting of:

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(phenylacetyl)-1,4-diazepan-1-
yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
yl)methyl}-4-chlorobenzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(1H-benzimidazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-
yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl}benzamide;

Appl'n. No. 10/070,954
 Amd. dated October 20, 2004
 Reply to Office Action of September 20, 2004

4-chloro-N-({5-[4-{3-{(2-hydroxyethyl)sulfonyl}anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-{[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl}thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(1-naphthoyl)piperazin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;


4-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

methyl 3-{[1-({5-[(4-nitrobenzoyl)amino)methyl]thien-2-yl)sulfonyl}piperidin-4-yl]amino}benzoate;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-2-hydroxybenzamide; and

N-({5-[4-{2-nitroanilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide.

13 (Previously presented). A method for the modulation of the JNK pathway, comprising administering an effective amount of a sulfonamide derivative according to formula I



wherein Ar¹ and Ar² are independently from each other substituted or unsubstituted aryl or heteroaryl groups;

X is O or S, preferably O;

R^1 is hydrogen or a C_1 - C_6 -alkyl group, or R^1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar^1 ;

n is an integer from 0 to 5, preferably between 1-3 and most preferred 1;

Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.

14 (Previously presented). A method according to claim 13 for the treatment or prevention of disorders associated with the abnormal expression or activity of JNK.

15 (Previously presented). A method according to claim 14 for the treatment or prevention of disorders associated with abnormal expression or activity of JNK2 and/or 3.

16 (Previously presented). A method in accordance with claim 13 for the treatment of neuronal disorders comprising administering an effective amount of sulfonamide derivative according to said formula I.

17 (Previously presented). A method in accordance with claim 13 for the treatment of autoimmune diseases comprising


administering an effective amount of sulfonamide derivative according to said formula I.

18 (Previously presented). A method in accordance with claim 13 for the treatment of cancer comprising administering an effective amount of sulfonamide derivative according to said formula I.


19 (Previously presented). A method in accordance with claim 13 for the treatment of cardiovascular diseases comprising administering an effective amount of sulfonamide derivative according to said formula I.

20 (Previously presented). A pharmaceutical composition containing at least one sulfonamide derivative according to claim 2 and a pharmaceutically acceptable carrier, diluent or excipient.

21 (Previously presented). Process for the preparation of a sulfonamide derivative according to claim 1, comprising reacting a' sulfonyl chloride V



with an amine VII or VIII



whereby $(R^6)_n$, L^1 and L^2 are as above defined.

22 (Previously presented). A process according to claim 21, wherein said sulfonyl chloride V is obtained by


a) coupling an amine of formula II:




where Ar^2 and R^1 are as defined above, with an acyl chloride of formula III:



where Ar^1 is as defined above, to provide an amide of formula IV:



b) sulfonating the amide of formula IV to provide a sulfonyl chloride V



23 (Previously presented). A method in accordance with claim 16, wherein said neuronal disorder is selected from the group consisting of epilepsy, Alzheimer's disease, Huntington's disease, Parkinson's disease, retinal diseases, spinal cord injury, and head trauma.

Appln. No. 10/070,954
Amd. dated October 20, 2004
Reply to Office Action of September 20, 2004

24 (Previously presented). A method in accordance with claim 17, wherein said autoimmune disease is selected from the group consisting of multiple sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis, asthma, septic shock, and transplant rejection.

25 (Previously presented). A method in accordance with claim 18, wherein said cancer is selected from the group consisting of breast-, colorectal-, and pancreatic cancer.

26 (Previously presented). A method in accordance with claim 19, wherein said cardiovascular disease is selected from the group consisting of stroke, arteriosclerosis, myocardial infarction, and myocardial reperfusion injury.